東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Lung inflammation in health and dise...

Wang, Yong-Xiao.

FindBook

Google Book

Amazon

博客來

Lung inflammation in health and disease.. Volume II

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Lung inflammation in health and disease./ edited by Yong-Xiao Wang.
其他作者:	Wang, Yong-Xiao.
出版者:	Cham :Springer International Publishing : : 2021.,
面頁冊數:	xvi, 384 p. :ill. (some col.), digital ;24 cm.
內容註:	1. Can GPCRs be targeted to control inflammation in asthma? -- 2. Cellular and molecular processes in pulmonary hypertension -- 3. INFLAMMATORY PATHWAYS IN SARCOIDOSIS -- 4. Innate Immune Responses and Pulmonary Diseases -- 5. Interstitial Lung Disease associated with Connective Tissue Diseases -- 6. Molecular mechanisms of vascular damage during lung injury -- 7. Neurotrophin Regulation and Signaling in Airway Smooth Muscle -- 8. Novel Thoracic MRI approaches for the assessment of pulmonary physiology and inflammation -- 9. Overview on Interactive Role of Inflammation, Reactive Oxygen Species and Calcium signaling in Asthma, COPD and Pulmonary Hypertension -- 10. Protein S-palmitoylation and lung diseases -- 11. Redox role of ROS and inflammation in pulmonary diseases -- 12. Semaphorin3E/PlexinD1 axis in asthma: what we know so far -- 13. Serine protease inhibitors to treat lung inflammatory diseases -- 14. Sex and Gender Differences in Lung Disease -- 15. Sex hormones and lung inflammation -- 16. Synopsis of Clinical Acute Respiratory Distress Syndrome (ARDS)
Contained By:	Springer Nature eBook
標題:	Pneumonia. -
電子資源:	https://doi.org/10.1007/978-3-030-68748-9
ISBN:	9783030687489

Lung inflammation in health and disease.. Volume II
Lung inflammation in health and disease.Volume II[electronic resource] /edited by Yong-Xiao Wang. - Cham :Springer International Publishing :2021. - xvi, 384 p. :ill. (some col.), digital ;24 cm. - Advances in experimental medicine and biology,v.13040065-2598 ;. - Advances in experimental medicine and biology ;v.1304..

1. Can GPCRs be targeted to control inflammation in asthma? -- 2. Cellular and molecular processes in pulmonary hypertension -- 3. INFLAMMATORY PATHWAYS IN SARCOIDOSIS -- 4. Innate Immune Responses and Pulmonary Diseases -- 5. Interstitial Lung Disease associated with Connective Tissue Diseases -- 6. Molecular mechanisms of vascular damage during lung injury -- 7. Neurotrophin Regulation and Signaling in Airway Smooth Muscle -- 8. Novel Thoracic MRI approaches for the assessment of pulmonary physiology and inflammation -- 9. Overview on Interactive Role of Inflammation, Reactive Oxygen Species and Calcium signaling in Asthma, COPD and Pulmonary Hypertension -- 10. Protein S-palmitoylation and lung diseases -- 11. Redox role of ROS and inflammation in pulmonary diseases -- 12. Semaphorin3E/PlexinD1 axis in asthma: what we know so far -- 13. Serine protease inhibitors to treat lung inflammatory diseases -- 14. Sex and Gender Differences in Lung Disease -- 15. Sex hormones and lung inflammation -- 16. Synopsis of Clinical Acute Respiratory Distress Syndrome (ARDS)

Lung diseases are leading causes of death and disability globally, with about 65 million people suffering from COPD, and 334 million from asthma. Each year, tens of millions of people develop and can die from lung infections such as pneumonia and TB. Systemic inflammation may induce and exacerbate local inflammatory diseases in the lungs, and local inflammation can in turn cause systemic inflammation. There is increasing evidence of the coexistence of systemic and local inflammation in patients suffering from asthma, COPD, and other lung diseases, and the co-morbidity of two or more local inflammatory diseases often occurs. For example, rheumatoid arthritis frequently occurs together with, and promotes the development of, pulmonary hypertension. This co-morbidity significantly impacts quality of life, and can result in death for some patients. Current treatment options for lung disease are neither always effective, nor condition-specific; there is a desperate need for novel therapeutics in the field. Additionally, the molecular and physiological significance of most major lung diseases is not well understood, which further impedes development of new treatments, especially in the case of coexistent lung diseases with other inflammatory diseases. Great progress has been made in recent years in many areas of the field, particularly in understanding the molecular geneses, regulatory mechanisms, signalling pathways, and cellular processes within lung disease, as well as basic and clinical technology, drug discovery, diagnoses, treatment options, and predictive prognoses. This is the first text to aggregate these developments. In two comprehensive volumes, experts from all over the world present state-of-the-art advances in the study of lung inflammation in health and disease. Contributing authors cover well-known as well as emerging topics in basic, translational, and clinical research, with the aim of providing researchers, clinicians, professionals, and students with new perspectives and concepts. The editors hope these books will also help to direct future research in lung disease and other inflammatory diseases, and result in the development of novel therapeutics.

ISBN: 9783030687489

Standard No.: 10.1007/978-3-030-68748-9doiSubjects--Topical Terms:

871060
Pneumonia.

LC Class. No.: RC771 / .L86 2021

Dewey Class. No.: 616.241

National Library of Medicine Call No.: WC 202

Lung inflammation in health and disease.. Volume II
LDR:04385nmm a2200349 a 4500 001 2240358
003 DE-He213
005 20210521172646.0
006 m d
007 cr nn 008maaau
008 211111s2021 sz s 0 eng d
020 $a 9783030687489 $q (electronic bk.)
020 $a 9783030687472 $q (paper)
024 7 $a 10.1007/978-3-030-68748-9 $2 doi
035 $a 978-3-030-68748-9
040 $a GP $c GP
041 0 $a eng
050 4 $a RC771 $b .L86 2021
060 4 $a WC 202
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
072 7 $a MJCM $2 thema
082 0 4 $a 616.241 $2 23
090 $a RC771 $b .L963 2021
245 0 0 $a Lung inflammation in health and disease. $n Volume II $h [electronic resource] / $c edited by Yong-Xiao Wang.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a xvi, 384 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v v.1304
505 0 $a 1. Can GPCRs be targeted to control inflammation in asthma? -- 2. Cellular and molecular processes in pulmonary hypertension -- 3. INFLAMMATORY PATHWAYS IN SARCOIDOSIS -- 4. Innate Immune Responses and Pulmonary Diseases -- 5. Interstitial Lung Disease associated with Connective Tissue Diseases -- 6. Molecular mechanisms of vascular damage during lung injury -- 7. Neurotrophin Regulation and Signaling in Airway Smooth Muscle -- 8. Novel Thoracic MRI approaches for the assessment of pulmonary physiology and inflammation -- 9. Overview on Interactive Role of Inflammation, Reactive Oxygen Species and Calcium signaling in Asthma, COPD and Pulmonary Hypertension -- 10. Protein S-palmitoylation and lung diseases -- 11. Redox role of ROS and inflammation in pulmonary diseases -- 12. Semaphorin3E/PlexinD1 axis in asthma: what we know so far -- 13. Serine protease inhibitors to treat lung inflammatory diseases -- 14. Sex and Gender Differences in Lung Disease -- 15. Sex hormones and lung inflammation -- 16. Synopsis of Clinical Acute Respiratory Distress Syndrome (ARDS)
520 $a Lung diseases are leading causes of death and disability globally, with about 65 million people suffering from COPD, and 334 million from asthma. Each year, tens of millions of people develop and can die from lung infections such as pneumonia and TB. Systemic inflammation may induce and exacerbate local inflammatory diseases in the lungs, and local inflammation can in turn cause systemic inflammation. There is increasing evidence of the coexistence of systemic and local inflammation in patients suffering from asthma, COPD, and other lung diseases, and the co-morbidity of two or more local inflammatory diseases often occurs. For example, rheumatoid arthritis frequently occurs together with, and promotes the development of, pulmonary hypertension. This co-morbidity significantly impacts quality of life, and can result in death for some patients. Current treatment options for lung disease are neither always effective, nor condition-specific; there is a desperate need for novel therapeutics in the field. Additionally, the molecular and physiological significance of most major lung diseases is not well understood, which further impedes development of new treatments, especially in the case of coexistent lung diseases with other inflammatory diseases. Great progress has been made in recent years in many areas of the field, particularly in understanding the molecular geneses, regulatory mechanisms, signalling pathways, and cellular processes within lung disease, as well as basic and clinical technology, drug discovery, diagnoses, treatment options, and predictive prognoses. This is the first text to aggregate these developments. In two comprehensive volumes, experts from all over the world present state-of-the-art advances in the study of lung inflammation in health and disease. Contributing authors cover well-known as well as emerging topics in basic, translational, and clinical research, with the aim of providing researchers, clinicians, professionals, and students with new perspectives and concepts. The editors hope these books will also help to direct future research in lung disease and other inflammatory diseases, and result in the development of novel therapeutics.
650 0 $a Pneumonia. $3 871060
650 1 4 $a Immunology. $3 611031
650 2 4 $a Human Physiology. $3 894102
650 2 4 $a Molecular Medicine. $3 890952
650 2 4 $a Pneumology/Respiratory System. $3 894348
700 1 $a Wang, Yong-Xiao. $3 2055493
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a Advances in experimental medicine and biology ; $v v.1304. $3 3495225
856 4 0 $u https://doi.org/10.1007/978-3-030-68748-9
950 $a Biomedical and Life Sciences (SpringerNature-11642)